Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adenosine administration for neonatal SVT

A P Green, K H Giattina

    Neonatal Network : NN
    |August 1, 1993
    PubMed
    Summary
    This summary is machine-generated.

    Adenosine effectively terminates neonatal supraventricular tachycardia (SVT) by slowing AV node conduction. Its short half-life minimizes adverse effects, but prophylaxis may be needed to prevent SVT reinitiation.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Discrimination of epimeric glycans and glycopeptides using IM-MS and its potential for carbohydrate sequencing.

    Nature chemistry·2013
    Same author

    Application of gauge R&R to the rigorous measurement of quantum yield in fluorescent organic solid state systems.

    The Review of scientific instruments·2012
    Same author

    Purification of supercoiled plasmid.

    Methods in molecular medicine·2011
    Same author

    HPLC purification of synthetic oligodeoxyribonucleotides containing base- and backbone-modified sequences.

    BioTechniques·1995
    Same author

    Structure/function analysis of the Ala116-->Lys121 region of endonuclease V by random targeted mutagenesis.

    Nucleic acids research·1993
    Same author

    Properties of an xeroderma pigmentosum revertant cell line expressing endonuclease V.

    Biochemical and biophysical research communications·1993
    Same journal

    A Quality Improvement Project to Increase Breastfeeding Rates in the NICU.

    Neonatal network : NN·2026
    Same journal

    Parental Advocacy in the NICU: A Unique Case of Infant Hypoglycemia Highlighting the Role of the Family in Improving Outcomes.

    Neonatal network : NN·2026
    Same journal

    Enteral Iron Supplementation.

    Neonatal network : NN·2026
    Same journal

    Enjoyment in Preterm Infants: Exploring Clinical and Research Perspectives in the Neonatal Intensive Care Unit.

    Neonatal network : NN·2026
    Same journal

    Building the Future Neonatal Nurse Practitioner Workforce: Reviewing Barriers and Strategies to Enrollment.

    Neonatal network : NN·2026
    Same journal

    What Does It Mean to Be a Professional?

    Neonatal network : NN·2026
    See all related articles

    Area of Science:

    • Cardiology
    • Pediatric Pharmacology

    Background:

    • Adenosine is a purine nucleoside that affects atrioventricular (AV) node conduction.
    • Supraventricular tachycardia (SVT) is a common arrhythmia in neonates.

    Purpose of the Study:

    • To review the use of adenosine as a first-line treatment for neonatal SVT.
    • To discuss dosing, administration, adverse effects, and monitoring of adenosine in infants.

    Main Methods:

    • Literature review of adenosine's efficacy and safety in neonatal SVT.
    • Analysis of pharmacokinetics, including half-life and adverse event profiles.
    • Summary of clinical administration guidelines and monitoring parameters.

    Main Results:

    • Adenosine is effective in terminating neonatal SVT with a recommended IV bolus dosing strategy.

    Related Experiment Videos

  • The drug has a very short half-life (0.6-10 seconds), leading to transient adverse effects.
  • Adverse effects include flushing, respiratory changes, irritability, bradycardia, and AV block, which are generally short-lived.

    • Conclusions:

    • Adenosine is the drug of choice for terminating neonatal SVT due to its rapid onset and short duration of action.
    • Close monitoring of infants is crucial during and after administration.
    • Prophylactic medication may be necessary if SVT recurrence is a concern.